The Tissue, Pathology and Bioinformatics Core A of the Moffitt Skin SPORE will be a multifunctional core devoted to the (1) optimal procurement, handling, processing, and pathologic characterization of tissues from patients with melanoma and non-melanoma skin cancer, as well as the (2) accurate compilation, storage, and analysis of clinical, pathologic, and investigational data generated from the Skin SPORE projects. The ultimate goals of Core A are to utilize pathology and informatics expertise and resources to both support the translation of hypotheses generated by the basic science-driven projects into accurate, clinically relevant conclusions that can be generalized to the prevention and/or treatment of melanoma and non-melanoma skin cancer, and to carry out and/or support the translational assays that are included within the trials of this Skin SPORE. Core A will take advantage of and supplement institutional shared resources for tissue and blood procurement, banking, nucleic acid isolation, and histopathology services including immunohistochemstry and tissue microarray production, as well as analytic microscopy facilities for digital imaging and analysis. Pathologic review, grading, and classification of all patient tissue specimens will be conducted by Core A. Institutional information technology resources will provide researchers a centralized location to store data, access analytical tools, in a seamless application environment managed by the Core. These facilities will be leveraged by the co-leaders, who will oversee and manage acquisition, storage, and distribution of all tissues and data derived in the course of the projects.
The Tissue, Pathology and Bioinformatics Core A of the Moffitt Skin SPORE will conduct the collection and storage of frozen tissue for lab-based translational studies (Projects 1, 2, and 3) as well as fixed tissue for molecular analyses and immunohistochemical staining/evaluation of molecular targets of interest (Projects 1, 2, 3, and 4). Core A will collect serum, hair follicle, and skin swabs for assessment of HPV and MCV infection (Project 4). The Core will storage and manage all data derived from these projects. The Core will also oversee the distribution of archived, clinically annotated biospecimens to support the Developmental Research and Career Development projects of the SPORE.
|Zhu, Genyuan; Brayer, Jason; Padron, Eric et al. (2018) OMIP-049: Analysis of Human Myelopoiesis and Myeloid Neoplasms. Cytometry A 93:982-986|
|Zhu, Genyuan; Nemoto, Satoshi; Mailloux, Adam W et al. (2018) Induction of Tertiary Lymphoid Structures With Antitumor Function by a Lymph Node-Derived Stromal Cell Line. Front Immunol 9:1609|
|Ramello, Maria C; Haura, Eric B; Abate-Daga, Daniel (2018) CAR-T cells and combination therapies: What's next in the immunotherapy revolution? Pharmacol Res 129:194-203|
|Eroglu, Zeynep; Zaretsky, Jesse M; Hu-Lieskovan, Siwen et al. (2018) High response rate to PD-1 blockade in desmoplastic melanomas. Nature 553:347-350|
|Phadke, Manali; Remsing Rix, Lily L; Smalley, Inna et al. (2018) Dabrafenib inhibits the growth of BRAF-WT cancers through CDK16 and NEK9 inhibition. Mol Oncol 12:74-88|
|Saglam, Ozlen; Naqvi, Syeda M H; Zhang, Yonghong et al. (2018) Female genitourinary tract melanoma: mutation analysis with clinicopathologic correlation: a single-institution experience. Melanoma Res 28:586-591|
|Eroglu, Zeynep; Chen, Y Ann; Gibney, Geoffrey T et al. (2018) Combined BRAF and HSP90 Inhibition in Patients with Unresectable BRAFV600E-Mutant Melanoma. Clin Cancer Res 24:5516-5524|
|Verduzco, Daniel; Kuenzi, Brent M; Kinose, Fumi et al. (2018) Ceritinib Enhances the Efficacy of Trametinib in BRAF/NRAS-Wild-Type Melanoma Cell Lines. Mol Cancer Ther 17:73-83|
|Prieto-Granada, Carlos; Castner, Nicholas; Chen, Ann et al. (2018) Behavior of Cutaneous Adnexal Malignancies: a Single Institution Experience. Pathol Oncol Res :|
|Abate-Daga, Daniel; Ramello, Maria C; Smalley, Inna et al. (2018) The biology and therapeutic management of melanoma brain metastases. Biochem Pharmacol 153:35-45|
Showing the most recent 10 out of 62 publications